# Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

> **NCT01908010** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 20 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** ABT-354
- **DRUG:** ABT-354
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01908010
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2013-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01908010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01908010, "Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01908010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*